TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Recommendation of “Hold” by Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given a consensus recommendation of “Hold” by the seven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $6.00.

Several research firms have recently weighed in on TCRX. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Finally, Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a research note on Thursday.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds have recently modified their holdings of TCRX. Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth about $25,000. Landscape Capital Management L.L.C. acquired a new position in TScan Therapeutics in the second quarter valued at about $25,000. HRT Financial LP acquired a new position in TScan Therapeutics in the fourth quarter valued at about $26,000. Public Employees Retirement System of Ohio purchased a new position in TScan Therapeutics during the first quarter worth about $28,000. Finally, Boothbay Fund Management LLC boosted its stake in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after buying an additional 8,121 shares during the period. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Trading Up 0.6%

Shares of TCRX stock opened at $0.78 on Thursday. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31. TScan Therapeutics has a twelve month low of $0.72 and a twelve month high of $2.57. The company’s 50-day moving average price is $0.89 and its 200-day moving average price is $1.01. The stock has a market cap of $51.20 million, a price-to-earnings ratio of -0.86 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.88 million. As a group, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.